Fibrate-Statin Combination Therapy and Change of Hepatic Steatosis-Related Indices in Patients with Dyslipidemia: A Retrospective Study Using Korean National Health Insurance Data
Endocrinology and Metabolism · 31.10.2026 · 41 (5) · 613-622
DOI: 10.3803/enm.2026.2891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.10.2026. Verfasst von Jong Han Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Se…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fibric Acids, Dyslipidemias, Fatty Liver. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The role of fibrates in modifying hepatic steatosis-related outcomes remains uncertain, particularly in real-world populations receiving statin therapy for dyslipidemia. We investigated the association between fibrate use and longitudinal changes in hepatic steatosis-related indices in statin-treated patients with moderate hypertriglyceridemia using nationwide health screening data.
Methods
We analyzed data from 307,992 adults with triglyceride level of 150–500 mg/dL receiving statin therapy, identified from the Korean National Health Insurance Service database. Participants were classified according to fibrate exposure (users vs. non-users). Hepatic steatosis was operationally assessed using two validated surrogate indices, the fatty liver index (FLI) and the hepatic steatosis index (HSI), measured at baseline and follow-up health checkups. Propensity score matching was performed to balance baseline characteristics. Subgroup analyses were conducted according to medication possession ratio (MPR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
- Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. endolife@kuh.ac.kr.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. skh2k@kuh.ac.kr.
Zitieren
APA
Choi, J. H., Kim, B., Han, K., Kim, D. L., Kim, S. K., & Song, K. (2026). Fibrate-Statin Combination Therapy and Change of Hepatic Steatosis-Related Indices in Patients with Dyslipidemia: A Retrospective Study Using Korean National Health Insurance Data. Endocrinology and Metabolism, 41(5), 613-622. https://doi.org/10.3803/enm.2026.2891
Vancouver
Choi JH, Kim B, Han K, Kim DL, Kim SK, Song K. Fibrate-Statin Combination Therapy and Change of Hepatic Steatosis-Related Indices in Patients with Dyslipidemia: A Retrospective Study Using Korean National Health Insurance Data. Endocrinology and Metabolism. 2026;41(5):613-622. doi:10.3803/enm.2026.2891
BibTeX
@article{Choi2026,
author = {Choi, Jong Han and Kim, Bongseong and Han, Kyungdo and Kim, Dong-Lim and Kim, Suk Kyeong and Song, Keeho},
title = {Fibrate-Statin Combination Therapy and Change of Hepatic Steatosis-Related Indices in Patients with Dyslipidemia: A Retrospective Study Using Korean National Health Insurance Data},
journal = {Endocrinology and Metabolism},
year = {2026},
volume = {41},
number = {5},
pages = {613--622},
doi = {10.3803/enm.2026.2891}
}
EUVIMED